Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis

Recent approval of the anti-interleukin (IL)-6 receptor antibody tocilizumab by US Food and Drug Administration (FDA) for slowing rate decline in pulmonary function adult patients with systemic sclerosis-associated interstitial lung disease is a welcome step towards better treatment outcomes sclerosis. Systemic has emerged as one major causes death very high burden unmet need. Tocilizumab second drug approved FDA this indication first biological agent any aspect sclerosis, 1 RocheRoche's Actemra/RoActemra becomes biologic therapy adults disease, rare, debilitating condition. https://www.roche.com/media/releases/med-cor-2021-03-05b.htmDate: March 5, 2021 Date accessed: April 1, Google Scholar underpinned substantial body translational medical research.